Sammy Hagar Urges FDA to Allow Experimental Cancer Treatment for Drummer’s Wife
Drummer David Lauser has been a fixture in the rock community for decades, and now his peers are doing everything they can to help him stave off a family tragedy.
As we previously reported, Lauser's wife Liza suffers from an inoperable tumor within her brainstem, and although her diagnosis is terminal, there's a small window of hope: an experimental treatment, called antineoplaston therapy, currently blocked by the FDA.
Lauser's friends in Chickenfoot, Night Ranger, and Mr. Big are staging a benefit concert for Liza Cozad-Lauser on Feb. 12, but they aren't stopping there. Singer Sammy Hagar, who's employed Lauser in his solo band for years, recently co-signed an urgent letter to the FDA, along with his Chickenfoot bandmates Michael Anthony and Joe Satriani, as well as Night Ranger's Jack Blades.
"There is no decision more personal than a decision about one’s personal health, particularly when it involves matters of life and death," reads one passage from the letter. "When government becomes a barrier to hope itself, it has exceeded its mandate."
Hagar and friends were joined by Dr. Ron Chapman, the director of the California Department of Public Health and the state health officer. "In the case of terminal cancer, and the patient’s and family’s willingness to consent to the administration of experimental treatment by a licensed medical clinic already involved in trials of this treatment with FDA approval, permitting treatment may provide some benefit to the patient," urged Chapman. "Please grant a compassionate waiver and honor this request for a single patient protocol."
"We are aware there are differences of opinion within the medical community regarding the efficacy and potential of antineoplastons in treating patients afflicted with this illness," continues the letter. "We are not asking the FDA to take a side in this debate. We are writing to simply urge that Liza be allowed to receive the treatment she seeks while research on the potential of antineoplastons for potential widespread use continues."